Rheumatic mitral valve disease is damage to the heart’s mitral valve caused by the body’s own immune system after a strep throat infection. The mitral valve sits between the two left chambers of the heart and controls blood flow from the upper chamber (left atrium) into the main pumping chamber (left ventricle). When rheumatic fever scars this valve, it can stiffen, narrow, or fail to close properly, disrupting normal blood flow. The disease often develops silently over two to three decades after the initial infection, making it one of the most delayed consequences of an untreated childhood illness.
How a Strep Infection Damages the Heart
The process starts with group A streptococcal pharyngitis, commonly known as strep throat. About two to three weeks after the infection, some people develop acute rheumatic fever, an autoimmune reaction where the immune system attacks the body’s own tissues. The reason is molecular mimicry: the strep bacterium produces a surface protein called M protein that closely resembles proteins found in human heart tissue. The immune system generates antibodies to fight the bacteria, but those same antibodies mistakenly target the heart.
The mitral valve is particularly vulnerable because many of the proteins the antibodies attack are concentrated on or near the valve’s inner lining. These include structural proteins in the valve’s basement membrane, collagen, and a protein called laminin that helps hold tissue together. Each bout of rheumatic fever deepens the inflammatory damage, causing the valve leaflets to thicken, scar, and fuse at their edges. This process doesn’t happen overnight. Over two to three decades, the accumulated scarring gradually narrows the valve opening or prevents it from sealing shut, or both.
Not everyone who gets strep throat develops rheumatic fever. The autoimmune response occurs in genetically susceptible people, which partly explains why the disease clusters in families and certain populations.
Two Types of Valve Damage
Rheumatic disease can harm the mitral valve in two distinct ways, and many patients end up with a combination of both.
Mitral stenosis occurs when scarring fuses the valve leaflets together at their edges (the commissures), narrowing the opening. Blood struggles to pass from the upper chamber into the pumping chamber, causing pressure to build up backward into the lungs. A normal mitral valve opening measures roughly 4 to 6 square centimeters. Severe stenosis is defined as a valve area of 1.5 square centimeters or less.
Mitral regurgitation happens when the scarred valve can’t close completely, allowing blood to leak backward into the upper chamber every time the heart contracts. The heart has to work harder to pump enough blood forward, and over time both the upper and lower chambers enlarge.
Symptoms and How They Develop
Rheumatic mitral valve disease is generally silent until the valve damage becomes severe enough to affect blood flow. Most people feel nothing for years or even decades. When symptoms finally appear, they typically include shortness of breath during physical activity, fatigue, and reduced exercise tolerance. These occur because the damaged valve forces blood to back up into the lungs, making it harder to get oxygen during exertion.
As the disease progresses, you may notice heart palpitations, swelling in the legs or ankles, or difficulty breathing while lying flat. Some people first learn about their valve disease when they develop an irregular heart rhythm called atrial fibrillation, which is common in this condition. In one study of 330 patients with rheumatic heart disease, 36% had atrial fibrillation. Among those patients, 8.3% experienced a stroke from blood clots forming in the enlarged upper chamber and traveling to the brain.
How It’s Diagnosed
Echocardiography (heart ultrasound) is the primary tool for diagnosing rheumatic mitral valve disease. It reveals the characteristic pattern of damage: the valve leaflets dome forward during filling rather than opening smoothly, the commissures are fused, and the leaflets themselves are thickened.
Specific measurements help determine severity. The anterior mitral valve leaflet is normally about 2 mm thick in children. A thickness of 3 mm or more in people under 20, 4 mm or more in people aged 20 to 39, and 5 mm or more in those 40 and older suggests rheumatic damage. Doctors also measure the valve opening area, blood flow speed across the valve, and pressure in the lung arteries to stage the disease from A (at risk) through D (symptomatic and severe).
For mitral regurgitation, the ultrasound looks for a jet of blood flowing backward through the valve. To qualify as abnormal, the regurgitant jet needs to be visible from two different angles, measure at least 2 centimeters in length, and last throughout the entire contraction phase of the heartbeat.
Staging From Mild to Severe
The American Heart Association and American College of Cardiology classify rheumatic mitral stenosis into four stages that guide treatment decisions:
- Stage A (At risk): Mild valve doming visible on ultrasound, but blood flow is normal and there are no symptoms.
- Stage B (Progressive): Commissural fusion with doming of the leaflets, but the valve area is still greater than 1.5 square centimeters. The upper chamber may be mildly to moderately enlarged.
- Stage C (Asymptomatic severe): The valve area has narrowed to 1.5 square centimeters or less, lung artery pressure is elevated above 50 mmHg, and the upper chamber is severely enlarged, yet the patient still feels no symptoms.
- Stage D (Symptomatic severe): Same anatomical criteria as Stage C, but now the patient experiences shortness of breath with exertion and reduced exercise tolerance.
Treatment Without Surgery
For patients with significant mitral stenosis and favorable valve anatomy, a catheter-based procedure called percutaneous balloon mitral valvuloplasty can widen the narrowed valve without open-heart surgery. A balloon-tipped catheter is threaded through a vein into the heart and inflated across the stenotic valve, splitting the fused commissures.
Not everyone is a good candidate. Doctors assess the valve using a scoring system (the Wilkins score) that rates four features on a scale of 1 to 4 each: how mobile the leaflets are, how thick they’ve become, how much calcium has built up, and how damaged the structures beneath the valve are. The total score ranges from 4 to 16. Patients scoring below 8 to 9 with no more than moderate regurgitation tend to have the best results from balloon valvuloplasty. Those scoring above 9 to 10, especially with significant leaking, generally need surgery instead.
Surgical Options
When the valve damage is too severe for a balloon procedure, surgery becomes necessary. There are two main approaches: repairing the existing valve or replacing it entirely with a mechanical or biological prosthetic valve.
Valve repair has the appeal of preserving your own tissue and avoiding lifelong blood thinners (which mechanical valves require). However, rheumatic valves are notoriously difficult to repair because the disease distorts the entire valve structure, not just one area. A study following patients for an average of six years found that repair and replacement had similar survival rates (around 33% mortality for both groups over the follow-up period). The critical difference was that patients who had valve repair were more than four times as likely to need a second operation. Patients who had previously undergone balloon valvuloplasty faced an even higher reoperation risk after repair.
Replacement with a mechanical valve is durable but requires taking blood-thinning medication for life. Biological (tissue) valves avoid that requirement but wear out over time, especially in younger patients, eventually necessitating another surgery. The choice depends on your age, lifestyle, and whether you can reliably take daily blood thinners.
Preventing the Disease
The most effective prevention is treating strep throat promptly with antibiotics before rheumatic fever can develop. For people who have already had one episode of rheumatic fever, long-term antibiotic prophylaxis is essential to prevent recurrent attacks that would cause further valve damage. This typically involves a penicillin injection every three to four weeks or oral penicillin taken twice daily. People allergic to penicillin can use alternative antibiotics.
The duration of prophylaxis is tailored to the individual but generally continues at least until age 21. Patients with established valve damage often need longer courses, sometimes lasting well into adulthood, because each new strep infection risks triggering another round of immune-mediated valve destruction.
Who Is Most Affected
Globally, an estimated 3.85 million new cases of rheumatic heart disease occurred in 2021, causing roughly 373,000 deaths. The disease disproportionately affects younger populations in low- and middle-income countries, where overcrowded living conditions facilitate strep transmission and access to antibiotics is limited. Mortality has declined in high-income countries over recent decades but remains a major cause of death in Sub-Saharan Africa, South Asia, and the Pacific Islands. The mitral valve is by far the most commonly affected valve, making rheumatic mitral valve disease the single largest contributor to this global burden.